GlobeNewswire

Compuware ThruPut Manager Empowers Next-Generation IT Staff to Optimize Mainframe Batch Execution

Share

New Visually Intuitive Insight into Workload Scheduling Helps Enterprises Ensure Performance of Critical Back-End Systems While Controlling Costs

 
  • Enterprises must ensure that critical mainframe batch workloads 1) are completed on time, 2) stay within cost parameters and 3) don't interfere with real-time processing that supports digital customer engagement.

  • Batch management can be jeopardized as mainframe responsibilities are transferred to a new generation of IT staff with far less platform experience, and as mainframe environments become increasingly complex.
     
  • ThruPut Manager and its new web interface address these core operational issues by providing IT staff with intuitive, actionable insight into how batch jobs are being initiated and executed, as well as their impact on cost. 

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today released a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

By implementing ThruPut Manager, enterprises can better safeguard performance of both batch and non-batch applications, while avoiding the significant adverse economic impact of preventable spikes in utilization as measured by Rolling 4-Hour Averages (R4HA), the metric upon which IBM bases its software licensing fees.

Additionally, with ThruPut Manager, enterprises can successfully transfer batch management responsibilities to a new generation of IT staff with far less hands-on platform experience-without exposing themselves to related risks such as missed batch execution deadlines, missed service level agreements and excess costs.

Safeguarding performance, controlling costs and smooth ownership transfers are more critical than ever given the growing importance of mainframe systems. According to a commissioned study conducted by Forrester Consulting on behalf of Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. And that percentage is expected to increase to 64 percent by 2019. The complete Forrester Opportunity Snapshot report, entitled "Modern Mainframe KPIs Are Key To A Successful Digital Strategy," can be found here.

Batch processing on the mainframe remains critical for many core business functions, such as reconciliation of financial transactions and re-pricing of mutual funds. In many cases, these batch workloads must be completed within a tight time-window. So as the size of a batch workload increases-and as other processing activity consumes an enterprise's finite platform resources-ops staff must take appropriate action. Those actions can include juggling the prioritization of jobs, assigning jobs to alternative LPARs and addressing data dependencies that may be holding up job initiation.

ThruPut Manager empowers IT staff to achieve these operational objectives by:

  • Making it easy to see whether batch jobs are meeting key service metrics-especially how quickly they start executing-and if not, what underlying issues are causing delays or non-initiation.
  • Graphically visualizing how it may be constraining less important workloads to minimize a R4HA peak.
  • Enabling operators to avoid unnecessary R4HA peaks by adaptively shifting workload priorities while still fulfilling business imperatives-rather than limiting them to inflexible "hard-capping."
  • Empowering mainframe ops teams to configure automation rules for initiating batch jobs based on parameters such as business impact, completion windows and workload size.

ThruPut Manager also helps ops teams avoid having too many batch jobs execute at the same time, commonly referred to as "over-initiating," which can cause them to compete for scarce CPU cycles-resulting in extended batch elapsed times and missed schedules, as can happen with IBM's WLM-managed initiators.

"Managing the system utilization and the user's expectations has been a real challenge for us," said Christopher Prenatt, who is the Lead Performance Engineer at Verizon. "The new ThruPut Manager GUI will give us the ability to visualize our batch workload for the first time. We can quickly see how long jobs are sitting in the queue and, if there is a problem, rapidly drill down to what the root cause may be. This will be a great addition for our application teams and ultimately help us get maximum value out of our mainframe."

"As mainframe workloads continue to increase, enterprise IT faces growing challenges in batch execution management," said Rich Ptak of IT analyst firm Ptak Associates. "Compuware ThruPut Manager provides much needed clarity and insight to fine-tune batch execution for optimal value easing budget stresses-even as less-experienced staff take on more mainframe responsibilities."

Compuware today also announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. zAdviser measures application quality, development velocity, and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts.

Today's announcements mark the 14th consecutive quarter that Compuware has announced significant innovation in the modernization and mainstreaming of the mainframe. This innovation is of vital importance to large enterprises that must get maximum business value from their mainframe environments-which are doing double-duty as both self-contained core systems of record, and as powerful back-end data and transaction processing systems for front-end customer-facing web and mobile applications.

"Enterprise CIOs have come to realize that high-cost, high-risk attempts to re-platform their supremely valuable mainframe applications make no sense. The less costly, less risky and higher return strategy is to simply adopt better technology for modernizing on platform and mainstreaming mainframe development, operations and security," said Chris O'Malley, CEO of Compuware. "Compuware is redefining what mainframe modernization means and is committed to delivering what customers need to enable them to adopt the smarter strategy."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

About GlobeNewswire

GlobeNewswire



Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Substansvärdet per den 30 november 20201.12.2020 10:00:00 CETPressmeddelande

Den 30 november 2020 var substansvärdet 278 kronor per aktie. Sista stängningskurs den 30 november 2020 var 265,00 kronor för A-aktien och 261,60 kronor för C-aktien. Stockholm den 1 december 2020 AB INDUSTRIVÄRDEN (publ) För ytterligare information kontakta: Sverker Sivall, Kommunikations- och hållbarhetschef, telefon 08-666 64 00 Lämnad för publicering den 1 december 2020, kl. 10:00. Bilaga Substansvarde_201201_sve

Arcoma lanserar nya röntgensystemet OMNERA 500A på amerikanska marknaden1.12.2020 08:30:00 CETPressmeddelande

2020-12-01 PRESSRELEASE Arcoma lanserar nya röntgensystemet OMNERA 500A på amerikanska marknaden Arcoma AB lanserar idag det nya röntgensystemet OMNERA 500A på den amerikanska marknaden. OMNERA 500A erbjuder nya intelligenta automatiseringsfunktioner för att förbättra arbetsflödet och effektiviteten men även patientvården. OMNERA 500A erbjuder enastående prestanda och intelligent automatisering med funktioner som sätter effektivitet och patientsäkerhet främst. Systemet har ny design och ett nytt modernt användargränsnitt med smarta funktioner som förenklar arbetsflödet och är utformat för att underlätta desinficering. OMNERA 500A har också ett helt nytt väggstativ och ett uppdaterat röntgenbord som förbättrar patient- och användarupplevelsen. OMNERA 500A lanseras genom Arcomas partner Canon Medical Systems USA på den årliga mässan RSNA som i år utförs digitalt. Mässan pågår hela denna vecka. För att se det nya systemet i Canon Medical Systems digitala monter, besök deras hemsida: https

Immunicum AB (publ) arrangerar virtuellt investerarevent den 9 december1.12.2020 08:00:00 CETPressmeddelande

Pressmeddelande 1 december 2020 Immunicum AB (publ) arrangerar virtuellt investerarevent den 9 december Immunicum AB (publ) (IMMU.ST) meddelar idag att bolaget kommer att arrangera ett virtuellt investerarevent onsdagen den 9 december klockan 15:00 CET. Under eventet kommer Immunicum att presentera en översikt av den föreslagna transaktionen med DCprime, inklusive en frågestund. Program och länk till det virtuella eventet kommer att finnas på www.immunicum.com innan eventet. Frågor kan skickas in på förhand och under eventet till ir@immunicum.com. FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sven Rohmann, VD Telefon: 08 732 8400 E-post: info@immunicum.com Investor Relations Jonas Rodny och Carolin Wiken Paues Åberg Communications Telefon: 076 190 90 51 E-post: ir@immunicum.com Media Relations Joanne Tudorica och Sophia Hergenhan, Ph.D. Trophic Communications Telefon: +49 171 351 2733 E-post: ir@immunicum.com Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immu

Sinch AB (publ): Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management30.11.2020 23:58:07 CETPressmeddelande

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har, i enlighet med Bolagets tidigare pressmeddelande idag den 30 november 2020 och med stöd av årsstämmans bemyndigande från den 15 maj 2020, beslutat om en riktad nyemission om 3 187 736 nya aktier till en teckningskurs om 1 050 kronor per aktie (”Nyemissionen”), motsvarande

Sinch AB (publ): Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management30.11.2020 17:36:35 CETPressmeddelande

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har uppdragit åt Carnegie och Handelsbanken Capital Markets (tillsammans ”Joint Bookrunners”) att utreda förutsättningarna för att genomföra en riktad nyemission om cirka 3,2 miljoner aktier, genom ett accelererat bookbuilding-förfarande (”Nyemissionen”). I samband med Nyemissionen, och i syfte att möta efterfrågan, har vissa s

Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML30.11.2020 16:31:31 CETPressmeddelande

STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS). FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta utvecklingsplanen och ger dessutom möjlighet till påskyndad handläggning av en registreringsansökan. Eprenetapopt (APR-246) är en småmolekylär läke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom